Online inquiry

IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7155MR)

This product GTTS-WQ7155MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CTGF gene. The antibody can be applied in Hepatic fibrosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001901.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1490
UniProt ID P29279
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7155MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13168MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ7211MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ8358MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ12374MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ11927MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ1683MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ11729MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ9053MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW